New drug combo aims to wipe out tough breast cancer before surgery
NCT ID NCT07017673
Summary
This study is testing whether adding a new immunotherapy drug called ivonescimab to standard chemotherapy before surgery is safe and more effective for people with early-stage triple-negative breast cancer (TNBC). About 34 participants will receive the drug combination for about 4.5 months, followed by surgery. The main goal is to see if the treatment completely eliminates the cancer in the breast and lymph nodes by the time of surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cedars-Sinai Medical Center Beverly Hills
RECRUITINGLos Angeles, California, 90211, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
-
Hunt Cancer Institute, an Affiliate of CS Cancer
RECRUITINGTorrance, California, 90505, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
-
Huntington Cancer Center, an Affiliate of CS Cancer
NOT_YET_RECRUITINGPasadena, California, 91105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.